Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Ra Pharmaceuticals Inc (RARX) USD0.001

Sell:$46.80 Buy:$46.81 Change: $0.06 (0.13%)
Market closed |  Prices as at close on 24 January 2020 | Switch to live prices |
Change: $0.06 (0.13%)
Market closed |  Prices as at close on 24 January 2020 | Switch to live prices |
Change: $0.06 (0.13%)
Market closed |  Prices as at close on 24 January 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system. It is developing its lead product candidate, RA101495, a self-administered subcutaneous (SC) injection. RA101495 is injected into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The Company is also developing RA101495 to treat other debilitating complement-mediated diseases such as generalized myasthenia gravis (gMG) and lupus nephritis (LN). It also focuses on discovery and preclinical programs targeting selective inhibition of other uncontrolled complement pathway factors to treat a variety of ophthalmic, renal and inflammatory diseases. The Company uses its Extreme Diversity platform, macrocyclic peptide chemistry technology which produces synthetic macrocyclic peptides.

Contact details

87 Cambridgepark Dr
United States
+1 (617) 4014060

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.21 billion
Shares in issue:
47.15 million
United States
US dollar

Key personnel

  • Edward Mathers
    Independent Chairman of the Board
  • Douglas Treco
    President, Chief Executive Officer, Co-Founder, Director
  • David Lubner
    Chief Financial Officer, Executive Vice President
  • Simon Read
    Chief Scientific Officer
  • Ramin Farzaneh-Far
    Chief Medical Officer
  • John King
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.